Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 25, 2008 Brian Lawler	Amgen Gets Its FDA Response Amgen investors can finally breathe a little sigh of relief after the biopharma giant announces that the Food and Drug Administration has finally approved its blood disorder drug.
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.
The Motley Fool October 26, 2010 Brian Orelli	Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth.
The Motley Fool November 24, 2008 Brian Orelli	Is Amgen's Nplate a Blockbuster? Amgen gets a positive recommendation from European officials for its blood-clotting drug.
The Motley Fool July 21, 2008 Brian Lawler	Amgen Rolls the Dice The Food and Drug Administration's impending ruling will determine the drugmaker's near-term fate. Investors, take note.
The Motley Fool January 28, 2008 Brian Lawler	A Wing and a Prayer for Amgen Amgen announces data from its top pipeline drug candidate. Investors, take note.
The Motley Fool July 8, 2009 Brian Orelli	Amgen Closes In on a Home Run Amgen already had a ball flying high above the outfield in its osteoporosis treatment, denosumab, but yesterday's clinical trial results were the wind that could push it out of the park.
The Motley Fool November 19, 2010 Brian Orelli	One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales.
The Motley Fool October 3, 2008 Brian Orelli	Amgen Draws Blood in Anemia-Drug War The pharmaceutical fights off rival Roche.
The Motley Fool November 21, 2008 Brian Orelli	Ligand and Glaxo Like the FDA's Answer Good news arrives for blood-clot buster Promacta.
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
The Motley Fool February 9, 2010 Brian Orelli	Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status.
The Motley Fool January 7, 2010 Brian Orelli	Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA.
The Motley Fool February 26, 2010 Brian Orelli	Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
The Motley Fool February 29, 2008 Brian Lawler	Amgen Playing Hardball There are new developments in the Amgen and Roche patent fight over their anemia drugs.
The Motley Fool August 31, 2010 Brian Orelli	Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior.
The Motley Fool September 17, 2008 Brian Orelli	Will Denosumab Strengthen Amgen's Bones? Recently passing its phase 3 trial will help get denosumab on the market. But two big questions remain: how well it worked, and whether anyone will buy it, given the drug's plentiful rivals.
The Motley Fool March 25, 2009 Brian Orelli	The FDA Leaves Pfizer in the Waiting Room The EU loves its new osteoporosis drug, but what about the U.S.?
BusinessWeek August 13, 2009 Arlene Weintraub	Amgen's Bone-Loss Drug Faces Marketing Hurdles Amgen is likely to receive FDA approval for denosumab, its new biologic bone-loss drug, but it may be a hard sell against cheaper generics.
The Motley Fool April 28, 2008 Brian Lawler	Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings.
The Motley Fool July 30, 2007 Brian Lawler	Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note.
The Motley Fool July 28, 2009 Brian Orelli	Amgen Secures Its Future Earnings and a marketing partnership -- oh my.
The Motley Fool July 31, 2009 Brian Orelli	Make Money Off Baby Boomers They're getting older whether they like it or not and need blood pressure, osteoporosis, and arthritis drugs and therapies.
The Motley Fool October 29, 2007 Brian Lawler	Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader.
The Motley Fool April 25, 2011 Brian Orelli	Dividend Investors Rejoice! Or Not. Amgen establishes a dividend, investors yawn.
The Motley Fool March 17, 2008 Brian Lawler	The Panelling on Amgen's Walls One FDA panel ruling is a win, another is much less upsetting than investors feared.
The Motley Fool April 21, 2011 Luke Timmerman	Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis.
The Motley Fool August 30, 2010 Brian Orelli	Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help.
The Motley Fool October 19, 2009 Brian Orelli	Still Waiting for Its Blockbuster Amgen announces a Food and Drug Administration delay for its long-awaited osteoporosis drug, Prolia, its treatment for postmenopausal osteoporosis.
The Motley Fool October 7, 2004 Charly Travers	Amgen's Next Blockbuster An osteoporosis drug could give the company its next big winner. With a P/E back in the mid 20s, the company is valued such that Amgen shareholders should be rewarded in the future if products are successful.
The Motley Fool March 19, 2008 Brian Lawler	Roche to Amgen: We Surrender Roche gives in to a judge's recommendation that it pay a higher royalty to Amgen on sales of its anemia drug Mircera.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool September 4, 2008 Brian Lawler	Sitting Tight in September This month, several drugmakers will hear about compounds awaiting approval, so we can expect some volatility in their share prices. Read on to see who's awaiting FDA news.
The Motley Fool May 14, 2007 Mike Havrilla	A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.
The Motley Fool October 20, 2005 Brian Gorman	Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors.
The Motley Fool June 13, 2008 Brian Lawler	Lilly Patches Its Pipeline An early-stage compound joins the pharmaceutical's upcoming roster.
The Motley Fool September 6, 2007 Brian Lawler	Amgen's Congressional Helpers Lawmakers push to ease restrictions on anemia compounds from Amgen and Johnson & Johnson. Investors, take note.
The Motley Fool May 27, 2009 Brian Orelli	A Partnership of the Heart Amgen, the large biotech company, exercises its right to license Cytokinetic's cardiac contractility program, including heart failure drug CK-1827452.
The Motley Fool July 28, 2008 Brian Lawler	Amgen's Bone-Building Boost The drugmaker gets good news about a top pipeline compound.
The Motley Fool March 25, 2010 Brian Orelli	More Than $5.3 Billion in Revenue Under Attack After dealing with the FDA, Amgen and J&J now have to deal with the Centers for Medicare & Medicaid Services.
The Motley Fool February 22, 2011 Brian Orelli	A Billion-Dollar Market to Open "Very Soon" Biosimilar drugs are finally coming to the U.S.
The Motley Fool July 12, 2004 Ben McClure	Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good.
The Motley Fool January 26, 2010 Brian Orelli	Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010.
The Motley Fool February 9, 2011 Luke Timmerman	Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"?
The Motley Fool May 29, 2008 Brian Lawler	Ligand Loses, for Now The FDA sends Ligand Pharmaceutical this message: approval unlikely, try again later.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
BusinessWeek January 14, 2010 Rob Waters	Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology.
The Motley Fool April 11, 2008 Brian Lawler	Amgen's Unsurprising Delay The FDA extends its review of an Amgen drug candidate.